Seven scientists who developed a coronavirus vaccine in Kazakhstan have tested it on themselves.
Scientists are feeling well and are continuing their work, Gadin.Net reports quoting TASS.
The first phase of clinical trials is expected to begin on 44 volunteers between the ages of 18 and 50 who do not have COVID-19 antibodies, following approval from the Kazakh Ministry of Health in September.
They will be monitored for 42 days after vaccination. In addition, the second phase of clinical trials is scheduled to begin in mid-October, which should be completed in December 2020.
Kazakhstan will produce vaccines if the clinical trials of the vaccines are positive.